- Home
- TGL vs LIXT Comparison
TGL vs LIXT Comparison
Compare TGL & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- LIXT
- Stock Information
- Founded
- TGL 2020
- LIXT 2005
- Country
- TGL United States
- LIXT United States
- Employees
- TGL N/A
- LIXT N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- LIXT Health Care
- Exchange
- TGL Nasdaq
- LIXT Nasdaq
- Market Cap
- TGL 4.8M
- LIXT 4.1M
- IPO Year
- TGL 2022
- LIXT N/A
- Fundamental
- Price
- TGL $1.62
- LIXT $1.33
- Analyst Decision
- TGL
- LIXT
- Analyst Count
- TGL 0
- LIXT 0
- Target Price
- TGL N/A
- LIXT N/A
- AVG Volume (30 Days)
- TGL 4.0M
- LIXT 22.1K
- Earning Date
- TGL 05-15-2025
- LIXT 05-12-2025
- Dividend Yield
- TGL N/A
- LIXT N/A
- EPS Growth
- TGL N/A
- LIXT N/A
- EPS
- TGL N/A
- LIXT N/A
- Revenue
- TGL $1,468,790.00
- LIXT N/A
- Revenue This Year
- TGL N/A
- LIXT N/A
- Revenue Next Year
- TGL N/A
- LIXT N/A
- P/E Ratio
- TGL N/A
- LIXT N/A
- Revenue Growth
- TGL N/A
- LIXT N/A
- 52 Week Low
- TGL $1.26
- LIXT $1.02
- 52 Week High
- TGL $203.50
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- TGL 43.01
- LIXT 50.90
- Support Level
- TGL $1.38
- LIXT $1.16
- Resistance Level
- TGL $2.06
- LIXT $1.49
- Average True Range (ATR)
- TGL 0.20
- LIXT 0.11
- MACD
- TGL 0.08
- LIXT 0.00
- Stochastic Oscillator
- TGL 45.00
- LIXT 51.45
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.